<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="327">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on March 04, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05251883</url>
  </required_header>
  <id_info>
    <org_study_id>SYSEC-KY-KS-2021-215</org_study_id>
    <nct_id>NCT05251883</nct_id>
  </id_info>
  <brief_title>A Study to Analyze Data on Metastatic Ovarian Cancer Using Multi-omics</brief_title>
  <official_title>A Study to Analyze Data on Metastatic Ovarian Cancer Using Multi-omics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      As one of the most common malignant tumors in women, the incidence of ovarian cancer is&#xD;
      expected to increase year by year. Due to its lack of typical symptoms and effective&#xD;
      screening methods, and the characteristics of implantation and distant metastasis, more than&#xD;
      70% of ovarian cancers were in the metastatic stage at the time of diagnosis. In this study,&#xD;
      the investigators will collect large samples of tissue from patients with ovarian cancer,&#xD;
      conduct multi-omics studies, and mapped the characteristic maps of the genome and&#xD;
      transcriptome of patients with metastatic ovarian cancer, and explore the molecular&#xD;
      mechanisms that can be used as new targets for the treatment of ovarian cancer. Besides, the&#xD;
      investigators will design and establish a database of metastatic ovarian cancer, integrate&#xD;
      multiple omics, imaging, pathology, and clinical information to study their potential&#xD;
      relevance, and analyze the relationship between various omics, imaging, pathology, and&#xD;
      prognosis, establish ovaries Cancer prediction model.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2022</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Progression-Free-Survival</measure>
    <time_frame>The sample will be tested immediately after they are taken from patients and the statistical analysis will be taken through study completion, an average of 3 year</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Ovarian Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      we will collect samples of tissue from patients with ovarian cancer, conduct multi-omics&#xD;
      studies, and mapped the characteristic maps of the genome and transcriptome of patients with&#xD;
      metastatic ovarian cancer.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with metastatic ovarian cancer from the gynecology clinical department of the&#xD;
        Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. female, â‰¥18 years old;&#xD;
&#xD;
          2. diagnosed as ovarian cancer by imaging and pathology;&#xD;
&#xD;
          3. did not receive any anti-tumor drug treatment before surgery in the gynecology&#xD;
             clinical department of the Sun Yat Sen Memorial Hospital of Sun Yat-Sen University;&#xD;
&#xD;
          4. received ovarian cancer surgery and Follow-up treatment;&#xD;
&#xD;
          5. Patients voluntarily participate in the research of this subject, have good&#xD;
             compliance, and can complete the enrollment by the requirements of the trial;&#xD;
&#xD;
          6. Sign informed consent and agree to the collection and use of their data.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have received other anti-tumor treatments or received tumor surgery&#xD;
             before enrollment;&#xD;
&#xD;
          2. Patients with malignant tumors in other parts;&#xD;
&#xD;
          3. Patients with uncontrollable neurological, psychiatric, or mental disorders;&#xD;
&#xD;
          4. Poor compliance and inability to Cooperate and describe treatment responders.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huaiwu Lu</last_name>
    <role>Study Director</role>
    <affiliation>The Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huaiwu Lu, Study Director</last_name>
    <phone>+86 18688395806</phone>
    <email>luhuaiwu@mail.sysu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Sun Yat-Sen Memorial Hospital of Sun Yat-Sen Universit</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huaiwu Lu, associate professor</last_name>
      <phone>+8618688395806</phone>
      <email>luhuaiwu@mail.sysu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://seer.cancer.gov/statfacts/html/ovary.html</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Weidle UH, Birzele F, Kollmorgen G, Rueger R. Mechanisms and Targets Involved in Dissemination of Ovarian Cancer. Cancer Genomics Proteomics. 2016 11-12;13(6):407-423. Review.</citation>
    <PMID>27807064</PMID>
  </reference>
  <reference>
    <citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12. Erratum in: CA Cancer J Clin. 2020 Jul;70(4):313.</citation>
    <PMID>30207593</PMID>
  </reference>
  <reference>
    <citation>Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017 May;41:3-14. doi: 10.1016/j.bpobgyn.2016.08.006. Epub 2016 Oct 3. Review.</citation>
    <PMID>27743768</PMID>
  </reference>
  <reference>
    <citation>Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013 Apr;49(6):1374-403. doi: 10.1016/j.ejca.2012.12.027. Epub 2013 Feb 26.</citation>
    <PMID>23485231</PMID>
  </reference>
  <reference>
    <citation>Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin. 2019 Jul;69(4):280-304. doi: 10.3322/caac.21559. Epub 2019 May 17. Review.</citation>
    <PMID>31099893</PMID>
  </reference>
  <reference>
    <citation>Deng K, Yang C, Tan Q, Song W, Lu M, Zhao W, Lou G, Li Z, Li K, Hou Y. Sites of distant metastases and overall survival in ovarian cancer: A study of 1481 patients. Gynecol Oncol. 2018 Sep;150(3):460-465. doi: 10.1016/j.ygyno.2018.06.022. Epub 2018 Jul 9.</citation>
    <PMID>30001833</PMID>
  </reference>
  <reference>
    <citation>Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017 Feb;14(1):9-32. doi: 10.20892/j.issn.2095-3941.2016.0084.</citation>
    <PMID>28443200</PMID>
  </reference>
  <reference>
    <citation>Piver MS. Treatment of ovarian cancer at the crossroads: 50 years after single-agent melphalan chemotherapy. Oncology (Williston Park). 2006 Sep;20(10):1156, 1158. Review.</citation>
    <PMID>17024868</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 9, 2022</study_first_submitted>
  <study_first_submitted_qc>February 22, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2022</study_first_posted>
  <last_update_submitted>February 22, 2022</last_update_submitted>
  <last_update_submitted_qc>February 22, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>multi-omics</keyword>
  <keyword>ovarian cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

